Release date: 4 April 2019
Promoter – Financial Intermediary
The project consists of the financing of research and development (R&D) in skin health and other investments of the promoter for the period 2019-2022.
The project covers the promoter's R&D programme with a therapeutic focus mainly on dermatology, notably the treatment of chronic immuno-inflammatory dermatological diseases, prevention and treatment of non-melanoma skin cancer, and treatment of dermatological orphan diseases.
- Industry - Manufacturing
Proposed EIB finance (Approximate amount)
EUR 120 million
Total cost (Approximate amount)
EUR 269 million
The project mainly concerns investments in R&D that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an Environmental Impact Assessment (EIA) under the Directive 2014/52/EU amending Directive 2011/92/EU. Full environmental details will be verified during the appraisal.
The promoter is a private company not operating in the Utilities sector and not having the status of a contracting authority. Thus it is not covered by EU Directives on procurement. However, the promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank's services will verify details during the project due diligence.
Signed - 27/03/2019
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The data provided on this page is therefore indicative and cannot be considered to represent official EIB policy (see also the Explanatory notes).